Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, QC, H2X 0A9, Canada.
Medical Imaging Research & Development, ArthroLab Inc, Montreal, QC, Canada.
Arthritis Res Ther. 2018 Mar 1;20(1):40. doi: 10.1186/s13075-018-1538-7.
The weight of recommendation for intra-articular therapies such as hyaluronic acid injections varies from one set of guidelines to another, and they have not yet reached unanimity with respect to the usefulness of intra-articular hyaluronic acid (IAHA) injections for the symptomatic treatment of knee osteoarthritis (OA). Among the reasons for the controversy is that the current literature provides inconsistent results and conclusions about such treatment. This study aimed at identifying determinants associated with a better response to IAHA treatment in knee OA.
Subjects were selected from the Osteoarthritis Initiative database. Participants were subjects who had radiographic OA, received one IAHA treatment, and had data on demographics and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores at visits before (T0) and after (T1; within 6 months) treatment. Pain was analyzed for demographic, clinical, and imaging characteristics at T0 and change over time (T0 to T1). Subjects with WOMAC pain > 0 at T0 were subdivided into Low, Moderate, and High pain groups based on tertile analysis. Further analyses were done with the High pain group (score ≥ 8), which was divided into responders (improvement in pain ≥ 20%) and nonresponders (unchanged or worsening of pain).
Participants (n = 310) received a total of 404 treatments (one per knee). In the Low and Moderate pain groups vs the High pain group, participants had significantly lower score at T0 (p < 0.001), and the Low vs High pain group had significantly lower BMI (p = 0.002), greater joint space width (JSW) (p = 0.010) and knee cartilage volume (p ≤ 0.009), and smaller synovial effusion (p = 0.033). In the High pain group, responders vs nonresponders were usually younger (p = 0.014), with greater cartilage volume in the medial compartment (p = 0.046), a trend toward greater JSW, and a significant improvement in all WOMAC scores (p < 0.001), while nonresponders showed worsening of symptoms.
This study identified reliable predictive determinants that can distinguish patients who could best benefit from IAHA treatment: high levels of knee pain, younger, and less severe structural damage. These could be implemented in clinical practice as a useful guide for physicians.
关节内治疗(如透明质酸注射)的推荐权重因一套指南而异,对于关节内透明质酸(IAHA)注射治疗膝关节骨关节炎(OA)的有效性,它们尚未达成一致。引起争议的原因之一是,目前的文献对于这种治疗提供了不一致的结果和结论。本研究旨在确定与 IAHA 治疗反应更好相关的决定因素。
从骨关节炎倡议数据库中选择受试者。受试者为影像学 OA 患者,接受了一次 IAHA 治疗,并且在治疗前(T0)和治疗后(T1;6 个月内)有关于人口统计学和西部安大略省和麦克马斯特大学骨关节炎指数(WOMAC)评分的数据。在 T0 时分析疼痛与人口统计学、临床和影像学特征之间的关系,并分析随时间的变化(T0 至 T1)。根据三分位分析,将 WOMAC 疼痛>0 的受试者分为低、中、高疼痛组。对高疼痛组(评分≥8)进一步分析,分为反应者(疼痛改善≥20%)和无反应者(疼痛不变或恶化)。
310 名受试者共接受了 404 次治疗(每膝一次)。在低疼痛和中疼痛组与高疼痛组相比,受试者在 T0 时的评分明显较低(p<0.001),而低疼痛组与高疼痛组相比,BMI 明显较低(p=0.002),关节间隙宽度(JSW)较大(p=0.010),膝关节软骨体积较大(p≤0.009),滑膜积液较小(p=0.033)。在高疼痛组中,反应者与无反应者通常更年轻(p=0.014),内侧关节软骨体积较大(p=0.046),JSW 呈增大趋势,所有 WOMAC 评分均显著改善(p<0.001),而无反应者则表现为症状恶化。
本研究确定了可靠的预测决定因素,可以区分最能从 IAHA 治疗中获益的患者:膝关节疼痛水平高、年龄较小、结构损伤较轻。这些因素可以作为临床实践中医生的有用指南。